In recent years, synthetic lethality has been recognized as a solid paradigm for anticancer
therapies. The discovery of a growing number of synthetic lethal targets has led to a …

Synthetic lethality (SL) is an innovative strategy in targeted anticancer therapy that exploits
tumor genetic vulnerabilities. This topic has come to the forefront in recent years, as …

Genome editing, specifically CRISPR/Cas9 technology, has revolutionized biomedical
research and offers potential cures for genetic diseases. Despite rapid progress, low …

DNA polymerase θ belongs to the A family of DNA polymerases and plays a key role in DNA
repair and damage tolerance, including double-strand break repair and DNA translesion …

Purpose: DNA polymerase theta (Polθ, encoded by the POLQ gene) is a DNA repair enzyme
critical for microhomology mediated end joining (MMEJ). Polθ has limited expression in …

Gene editing through repair of CRISPR-Cas9-induced chromosomal breaks offers a means
to correct a wide range of genetic defects. Directing repair to produce desirable outcomes by …

Inhibition of the low fidelity DNA polymerase Theta (Polθ) is emerging as an attractive,
synthetic-lethal antitumor strategy in BRCA-deficient tumors. Here we report the AI-enabled …

Repair of DNA damage is essential for the maintenance of genome stability and cell viability.
DNA double strand breaks (DSBs) constitute a toxic class of DNA lesion and multiple …

DNA polymerase theta (Polθ) has recently emerged as a new attractive synthetic lethal
target involved in DNA damage repair. Inactivating Polθ alone or in combination with PARP …

DNA damage response (DDR) pathway is the coordinated cellular network dealing with the
identification, signaling, and repair of DNA damage. It tightly regulates cell cycle progression …